<DOC>
	<DOCNO>NCT01661868</DOCNO>
	<brief_summary>This research study way gain new knowledge drug call olaparib woman either : 1 ) never receive PARP inhibitor treat ovarian cancer ( group 1 ) 2 ) participant receive PARP inhibitor treat ovarian cancer , exception olaparib ( group 2 ) . PARP inhibitor drug tht prevent cancer cell repair DNA . In research study , look see well drug olaparib work woman never receive PARP inhibitor recurrent ovarian cancer well receive prior PARP inhibitor whose cancer re-grown receive PARP inhibitor .</brief_summary>
	<brief_title>Olaparib Patients With Recurrent BRCA Deficient Ovarian Cancer</brief_title>
	<detailed_description>Olaparib tablet take twice daily , orally , treatment cycle last 4 week . On day 1 , 8 , 12 22 first 2 cycle day 1 cycle , subject physical exam , ask question general health , specific question problem might medications take . Tumor ass either CT MRI scan every 2 cycle ( every 2 month ) . Tumor biopsies optional study . Only participants receive PARP inhibitor past ask biopsy tumor .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Histologically confirm ovarian , peritoneal fallopian tube cancer recur follow platinumbased regimen use initial diagnosis Measurable disease Estimated life expectancy great 16 week Normal organ marrow function Evidence nonchildbearing status woman childbearing potential Able swallow oral medication Pregnant breastfeeding Prior PARP inhibitor use another cancer breast cancer Receiving study agent anticancer treatment Known brain metastasis History allergic reaction attribute compound similar chemical biologic composition olaparib Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive hear failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement History different malignancy unless diseasefree least 5 year Currently experience seizure currently treat antiepileptic seizure Human immunodeficiency virus ( HIV ) positive combination antiretroviral therapy Presence gastrointestinal disorder , investigator 's opinion , likely interfere absorption olaparib , patient 's ability take regular oral medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>BRCA1 mutation</keyword>
	<keyword>BRCA2 mutation</keyword>
</DOC>